1. Paoli A, Rubini A, Volek JS, Grimaldi KA. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr. 2013;67:789–96.

2. Seyfried TN, Flores RE, Poff AM, D’Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis. 2014;35:515–27.

3. Vidali S, Aminzadeh S, Lambert B, Rutherford T, Sperl W, Kofler B, et al. Mitochondria: the ketogenic diet—a metabolism-based therapy. Int J Biochem Cell Biol. 2015;63:55–9.

4. Seyfried TN, Yu G, Maroon JC, D’Agostino DP. Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. Nutr Metab (Lond). 2017;14:19.

5. Klement RJ, Kämmerer U. Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond). 2011;8:75.

6. Allen BG, Bhatia SK, Anderson CM, Eichenberger-Gilmore JM, Sibenaller ZA, Mapuskar KA, et al. Ketogenic diets as an adjuvant cancer therapy: history and potential mechanism. Redox Biol. 2014;2C:963–70.

7. Klement RJ, Champ CE. Calories, carbohydrates, and cancer therapy with radiation: exploiting the five R’s through dietary manipulation. Cancer Metasta Rev. 2014;33:217–29.

8. Woolf EC, Syed N, Scheck AC. Tumor metabolism, the ketogenic diet and β-hydroxybutyrate: novel approaches to adjuvant brain tumor therapy. Front Mol Neurosci. 2016;9:122.

9. Winter SF, Loebel F, Dietrich J. Role of ketogenic metabolic therapy in malignant glioma: a systematic review. Crit Rev Oncol Hematol. 2017;112:41–58.

10. Huebner J, Marienfeld S, Abbenhardt C, Ulrich C, Muenstedt K, Micke O, et al. Counseling patients on cancer diets: a review of the literature and recommendations for clinical practice. Anitcancer Res. 2014;34:39–48.

11. Howick J. The philosophy of evidence-based medicine. 1st ed. Oxford: Wiley; 2011.

12. Walach H, Falkenberg T, Fønnebø V, Lewith G, Jonas WB. Circular instead of hierarchical: methodological principles for the evaluation of complex interventions. BMC Med Res Methodol. 2006;6:29.

13. Walach H, Loef M. Using a matrix-analytical approach to synthesizing evidence solved incompatibility problem in the hierarchy of evidence. J Clin Epidemiol. 2015;68:1251–60.

14. Tan-Shalaby JL, Carrick J, Edinger K, Genovese D, Liman AD, Passero VA, et al. Modified Atkins diet in advanced malignancies: final results of a safety and feasibility trial within the Veterans Affairs Pittsburgh Healthcare System. Nutr Metab (Lond). 2016;13:52.

15. Bandyopadhyay PS, Brittan G Jr, Taper ML. Belief, evidence, and uncertainty: problems of Epistemic inference. 1st ed. Berlin: Springer Nature; 2016.

16. Carnap R. On the application of inductive logic. Philos Phenomenol Res. 1947;8:133–48.

17. Pawson R, Greenhalgh T, Harvey G, Walshe K. Realist review–a new method of systematic review designed for complex policy interventions. J Health Serv Res Policy. 2005;10:21–34.

18. Greenhalgh T, Wong G, Westhorp G, Pawson R. Protocol–realist and meta-narrative evidence synthesis: evolving standards (RAMESES). BMC Med Res Methodol. 2011;11:115.

19. Wong G, Greenhalgh T, Westhorp G, Buckingham J, Pawson R, Pawson R, et al. RAMESES publication standards: realist syntheses. BMC Med. 2013;11:21.

20. Aronson JL. A realist philosophy of science. 1st ed. London: The Macmillan Press Ltd; 1984.

21. Pérez-Guisado J, Muñoz-Serrano A, Alonso-Moraga Á. Spanish Ketogenic Mediterranean diet: a healthy cardiovascular diet for weight loss. Nutr J. 2008;7:30.

22. Clemens Z, Kelemen A, Fogarasi A, Tóth C. Childhood absence epilepsy successfully treated with the Paleolithic Ketogenic diet. Neurol Ther. 2013;2:71–6.

23. Nebeling LC, Lerner E. Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc. 1995;95:693–7.

24. Jenkins DJA, Wong JMW, Kendall CWC, Esfahani A, Ng VWY, Leong TCK, et al. The effect of a plant-based low-carbohydrate (“Eco-Atkins”) diet on body weight and blood lipid concentrations in hyperlipidemic subjects. Arch Intern Med. 2009;169:1046–54.

25. Walach H. Mehr Daten? Mehr denken? Umdenken! Forschende Komplementärmedizin/Res Complement Med. 2016;23:3–5.

26. Fearon KC, Borland W, Preston T, Tisdale MJ, Shenkin A, Calman KC. Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr. 1988;47:42–8.

27. Nebeling L, Miraldi F, Shurin S, Lerner E. Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr. 1995;14:202–8.

28. Chu-Shore CJ, Thiele EA. Tumor growth in patients with tuberous sclerosis complex on the ketogenic diet. Brain Dev. 2010;32:318–22.

29. Schmidt M, Pfetzer N, Schwab M, Strauss I, Kämmerer U. Effects of a ketogenic diet on the quality of life in 16 patients with advanced cancer: a pilot trial. Nutr Metab (Lond). 2011;8:54.

30. Schroeder U, Himpe B, Pries R, Vonthein R, Nitsch S, Wollenberg B. Decline of lactate in tumor tissue after ketogenic diet: in vivo microdialysis study in patients with head and neck cancer. Nutr Cancer. 2013;65:843–9.

31. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neurooncol. 2014;117:125–31.

32. Branca JJV, Pacini S, Ruggiero M. Effects of Pre-surgical vitamin D supplementation and Ketogenic Diet in a patient with recurrent breast cancer. Anticancer Res. 2015;35:5525–32.

33. Schwartz K, Chang HT, Nikolai M, Pernicone J, Rhee S, Olson K, et al. Treatment of glioma patients with ketogenic diets: report of two cases treated with an IRB-approved energy-restricted ketogenic diet protocol and review of the literature. Cancer Metab. 2015;3:3.

34. Strowd RE, Cervenka MC, Henry BJ, Kossoff EH, Hartman AL, Blakeley JO. Glycemic modulation in neuro-oncology: experience and future directions using a modified Atkins diet for high-grade brain tumors. Neurooncol Pract. 2015;2:127–36.

35. Jansen N, Walach H. The development of tumours under a ketogenic diet in association with the novel tumour marker TKTL1: a case series in general practice. Oncol Lett. 2016;11:584–92.

36. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: I. Initial clinical experience with six prospectively studied patients. BMC Res Notes. 2016;9:143.

37. Artzi M, Liberman G, Vaisman N, Bokstein F, Vitinshtein F, Aizenstein O, et al. Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. J Neurooncol. 2017;132:267–75.

38. Tisdale MJ, Brennan RA, Fearon KC. Reduction of weight loss and tumour size in a cachexia model by a high fat diet. Br J Cancer. 1987;56:39–43.

39. Tisdale MJ, Brennan RA. A comparison of long-chain triglycerides and medium-chain triglycerides on weight loss and tumour size in a cachexia model. Br J Cancer. 1988;58:580–3.

40. Beck SA, Tisdale MJ. Effect of insulin on weight loss and tumour growth in a cachexia model. Br J Cancer. 1989;59:677–81.

41. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P. Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer. 2003;89:1375–82.

42. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN. The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond). 2007;4:5.

43. Freedland SJ, Mavropoulos J, Wang A, Darshan M, Demark-Wahnefried W, Aronson WJ, et al. Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate. 2008;68:11–9.

44. Otto C, Kaemmerer U, Illert B, Muehling B, Pfetzer N, Wittig R, et al. Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. BMC Cancer. 2008;8:122.

45. Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Rokhfeld D, Pollak M, Zhao Y, et al. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res. 2009;2:557–65.

46. Masko EM, Thomas JA 2nd, Antonelli JA, Lloyd JC, Phillips TE, Poulton SH, et al. Low-carbohydrate diets and prostate cancer: how Low Is “Low Enough”? Cancer Prev Res. 2010;3:1124–31.

47. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;7:74.

48. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315.

49. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE. 2012;7:e36197.

50. Kim HS, Masko EM, Poulton SL, Kennedy KM, Pizzo SV, Dewhirst MW, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int. 2012;110:1062–9.

51. Allen BG, Bhatia SK, Buatti JM, Cancer C, Published R, June O. Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer Xenografts Ketogenic diets enhance oxidative stress and radio- chemo-therapy responses in lung cancer xenografts. Clin Cancer Res. 2013;19:3905–13.

52. Caso J, Masko EM, Thomas JA II, Poulton SH, Dewhirst M, Pizzo SV, et al. The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate. 2013;73:449–54.

53. Poff AM, Ari C, Seyfried TN, Agostino DPD. The Ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS ONE. 2013;8:e65522.

54. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: effect on Myeloid-Derived suppressor cells and NK cells. J Immunol. 2014;191:1486–95.

55. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, et al. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18.

56. Zhuang Y, Chan DK, Haugrud AB, Miskimins WK. Mechanisms by which low glucose enhances the cytotoxicity of metformin to cancer cells both in vitro and in vivo. PLoS ONE. 2014;9:e108444.

57. Gluschnaider U, Hertz R, Ohayon S, Smeir E, Smets M, Pikarsky E, et al. Long-chain fatty acid analogues suppress breast tumorigenesis and progression. Cancer Res. 2014;74:6991–7002.

58. Healy ME, Chow JDY, Byrne FL, Breen DS, Leitinger N, Li C, et al. Dietary effects on liver tumor burden in mice treated with the hepatocellular carcinogen diethylnitrosamine. J Hepatol. 2015;62:599–606.

59. Hao G-W, Chen Y-S, He D-M, Wang H-Y, Wu G-H, Zhang B. Growth of human colon cancer cells in nude mice is delayed by Ketogenic diet with or without Omega-3 fatty acids and medium-chain triglycerides. Asian Pac J Cancer Prev. 2015;16:2061–8.

60. Morscher RJ, Aminzadeh-Gohari S, Feichtinger RG, Mayr JA, Lang R, Neureiter D, et al. Inhibition of neuroblastoma tumor growth by Ketogenic Diet and/or calorie restriction in a CD1-Nu mouse model. PLoS ONE. 2015;10:e0129802.

61. Poff AM, Ward N, Seyfried TN, Arnold P, D’Agostino DP. Non-toxic metabolic management of metastatic cancer in VM mice: novel combination of Ketogenic Diet, Ketone supplementation, and hyperbaric oxygen therapy. PLoS ONE. 2015;10:e0127407.

62. Woolf EC, Curley KL, Liu Q, Turner GH, Charlton JA, Preul MC, et al. The Ketogenic Diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model. PLoS One. 2015;10:e0130357.

63. Stemmer K, Zani F, Habegger KM, Neff C, Kotzbeck P, Bauer M, et al. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in Mice. Diabetologia. 2015;58:2414–23.

64. Dang MT, Wehrli S, Dang CV, Curran T. The Ketogenic Diet does not affect growth of Hedgehog pathway Medulloblastoma in Mice. PLoS ONE. 2015;10:e0133633.

65. Martuscello RT, Vedam-Mai V, McCarthy DJ, Schmoll ME, Jundi MA, Louviere CD, et al. A supplemented high-fat low-carbohydrate diet for the treatment of glioblastoma. Clin Cancer Res. 2016;22:2482–95.

66. Liśkiewicz AD, Kasprowska D, Wojakowska A, Polański K, Lewin-Kowalik J, Kotulska K, et al. Long-term high fat Ketogenic Diet promotes renal tumor growth in a rat model of Tuberous Sclerosis. Sci Rep. 2016;6:21807.

67. Lussier DM, Woolf EC, Johnson JL, Brooks KS, Blattman JN, Scheck AC. Enhanced immunity in a mouse model of malignant glioma is mediated by a therapeutic Ketogenic diet. BMC Cancer. 2016;16:10.

68. Xia S, Lin R, Jin L, Zhao L, Kang H-B, Pan Y, et al. Prevention of dietary-fat-fueled Ketogenesis attenuates BRAF V600E tumor growth. Cell Metab. 2017;25:358–73.

69. Allott EH, Macias E, Sanders S, Knudsen BS, Thomas G V, Hursting SD, et al. Impact of carbohydrate restriction in the context of obesity on prostate tumor growth in the Hi-Myc transgenic mouse model. Prostate Cancer Prostatic Dis. 2017;20:165–71.

70. Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44:1843–52.

71. Zahra A, Fath MA, Opat E, Mapuskar KA, Bhatia SK, Ma DC, et al. Consuming a Ketogenic Diet while receiving radiation and chemotherapy for locally advanced lung cancer and pancreatic cancer: The University of Iowa experience of two phase 1 clinical trials. Radiat Res. 2017;187:743–54.

72. Lv M, Zhu X, Wang H, Wang F, Guan W. Roles of caloric restriction, ketogenic diet and intermittent fasting during initiation, progression and metastasis of cancer in animal models: a systematic review and meta-analysis. PLoS ONE. 2014;9:e115147.

73. Klement RJ, Champ CE, Otto C, Kämmerer U. Anti-tumor effects of Ketogenic diets in Mice: a meta-analysis. PLoS ONE. 2016;11:e0155050.

74. Fearon KC, Tisdale MJ, Preston T, Plumb JA, Calman KC. Failure of systemic ketosis to control cachexia and the growth rate of the Walker 256 carcinosarcoma in rats. Brit J Cancer. 1985;52:87–92.

75. Beck SA, Tisdale MJ. Nitrogen excretion in cancer cachexia and its modification by a high fat diet in Mice. Cancer Res. 1989;49:3800–4.

76. Otto C, Klingelhöffer C, Biggermann L, Melkus G, Mörchel P, Jürgens C, et al. Analysis of the metabolism of Ketone Bodies and lactate by gastrointestinal tumor cells in vitro. Aktuel Ernahrungsmed. 2014;39:51–9.

77. Hao G, Wang H, He D, Chen Y, Wu G, Zhang B. Effect of ketogenic diet on growth of human colon cancer cells in nude mice. Chinese J Clin Oncol. 2014;41:1154–7.

78. Liu R-Q, Liu M-F, Jiang X-C, Guo Z-Z, Dong J-Y, Chen R, et al. Ketogenic diet affects tumor growth in the mouse model of EMT-6 breast cancer. Chinese J Cancer Prev Treat. 2015;22:827–31.

79. De Feyter HM, Behar KL, Rao JU, Madden-Hennessey K, Ip KL, Hyder F, et al. A ketogenic diet increases transport and oxidation of ketone bodies in RG2 and 9L gliomas without affecting tumor growth. Neuro Oncol. 2016;18:1079–87.

80. Healy ME, Lahiri S, Hargett SR, Chow JDY, Byrne FL, Breen DS, et al. Dietary sugar intake increases liver tumor incidence in female mice. Sci Rep. 2016;6:22292.

81. Brünings W. Beiträge zum Krebsproblem. 1. Mitteilung: Ueber eine diätetisch-hormonale Beeinflussung des Krebses. Münch Med Wschr. 1941;88:117–23.

82. Brünings W. Beiträge zum Krebsproblem. 2. Mitteilung: Klinische Anwendungen der diätetisch-hormonalen Krebsbeeinflussung (“Entzuckerungsmethode”). Münch Med Wschr 1942; 89: 71–6.

83. Schulte G, Schütz H. Insulin in der Krebsbehandlung. Münch Med Wschr. 1942;89:648–50.

84. Zuccoli G, Marcello N, Pisanello A, Servadei F, Vaccaro S, Mukherjee P, et al. Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: case report. Nutr Metab. 2010;7:33.

85. Moore K. Using the restricted ketogenic diet for brain cancer management: comments from neuro-oncologist. In: Seyfried TN, editor. Cancer as a metabolic disease: on the origin, management, and prevention of cancer. Hoboken: Wiley; 2012. p. 397–400.

86. Fine EJ, Segal-isaacson CJ, Feinman RD, Herszkopf S, Romano MC, Tomuta N, et al. Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition. 2012;28:1028–35.

87. Tóth C, Clemens Z. Halted progression of soft palate cancer in a patient treated with the paleolithic Ketogenic Diet alone. Am J Med Case Reports. 2016;4:288–92.

88. Schwalb M, Taubmann M, Hines S, Reinwald H, Ruggiero M. Clinical observation of a novel, complementary, immunotherapeutic approach based on Ketogenic diet, chondroitin sulfate, vitamin D 3, oleic acid and a fermented milk and colostrum product. Am J Immunol. 2016;12:91–8.

89. Abdelbary M, Elsakka A, Salah H, Mokhtar W, Abdelzaher E. Does Metabolic management of gliomas using restricted Ketogenic diet combined with hyperbaric oxygen therapy (HBOT) improve clinical outcome and reduce epileptic risk? (poster presentation). Tampa: Metabolic Therapeutics Conference; 2017.

90. Klement RJ. Restricting carbohydrates to fight head and neck cancer—is this realistic? Cancer Biol Med. 2014;11:145–61.

91. Warburg O, Posener K, Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Zeitschr. 1924;152:309–43.

92. Fine EJ, Miller A, Quadros EV, Sequeira JM, Feinman RD. Acetoacetate reduces growth and ATP concentration in cancer cell lines which over-express uncoupling protein 2. Cancer Cell Int. 2009;9:14.

93. Seyfried TN, Shelton LM. Cancer as a metabolic disease. Nutr Metab (Lond). 2010;7:7.

94. Seyfried TN. Cancer as a metabolic disease: on the origin, management, and prevention of cancer. Hoboken: Wiley; 2012.

95. Marchut E, Gumińska M, Kedryna T. The inhibitory effect of various fatty acids on aerobic glycolysis in Ehrlich ascites tumour cells. Acta Biochim Pol. 1985;33:7–16.

96. Nakahara W. Studies on Lymphoid activity. VI. Immunity to transplanted cancer induced by injection of olive oil. J Exp Med. 1921;35:493–505.

97. Nakahara W. Effect of fatty acids on the resistance of mice to transplanted cancer. J Exp Med. 1924;40:363–73.

98. Fine EJ, Feinman RD. Insulin, carbohydrate restriction, metabolic syndrome and cancer. Exp Rev Endocrin Metab. 2014;10:15–24.

99. Klement RJ, Fink MK. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis. 2016;5:e193.

100. Sherwin RS, Hendler R, Felig P. Effect of ketone infusions on amino acid and nitrogen metabolism in man. J Clin Invest. 1975;55:1382–90.

101. Klement RJ, Sweeney RA. Impact of a ketogenic diet intervention during radiotherapy on body composition: II. Protocol of a randomised phase I study (KETOCOMP). Clin Nutr ESPEN. 2016;12:e1–6.

102. Ahmad IM, Aykin-Burns N, Sim JE, Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2- and H2O2 Mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem. 2005;280:4254–63.

103. Weiser MA, Cabanillas ME, Konopleva M, Thomas DA, Pierce SA, Escalante CP, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179–85.

104. McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery. 2008;63:286–91.

105. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27:1082–6.

106. Lamkin DM, Spitz DR, Shahzad MMK, Zimmerman B, Lenihan DL, DeGeest K, et al. Glucose as a prognostic factor in Ovarian Carcinoma. Cancer. 2009;115:1021–7.

107. Erickson K, Patterson RE, Flatt SW, Natarajan L, Parker BA, Heath DD, et al. Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer. J Clin Oncol. 2011;29:54–60.

108. Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, Bacon L, Rivera D, Urzua L, et al. Impact of diabetes and Hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012;2012:732027.

109. Minicozzi P, Berrino F, Sebastiani F, Falcini F, Vattiato R, Cioccoloni F, et al. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease. Eur J Cancer. 2013;49:3881–8.

110. Mayer A, Vaupel P, Struss H-G, Giese A, Stockinger M, Schmidberger H. Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. Strahlenther Onkol. 2014;190:933–8.

111. Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar B-A, et al. Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide. J Neurooncol. 2015;124:119–26.

112. Monzavi-Karbassi B, Gentry R, Kaur V, Siegel ER, Jousheghany F, Medarametla S, et al. Pre-diagnosis blood glucose and prognosis in women with breast cancer. Cancer Metab. 2016;4:7.

113. Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, et al. The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. Acta Oncol (Madr). 2016;55:201–7.

114. Klement RJ, Champ CE. Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. Brain. 2017;140:e16.

115. Fine EJ, Champ CE, Feinman RD, Márquez S, Klement RJ. An evolutionary and mechanistic perspective on dietary carbohydrate restriction in Cancer Prevention. J Evo Health. 2016;1:15.

116. Clemens Z, Tóth C. Vitamin C and disease: insights from the evolutionary perspective. J Evo Health. 2016;1:13.

117. Klement RJ, Feinman RD, Gross EC, Champ CE, D’Agostino DP, Fine EJ, et al. Need for new review of article on ketogenic dietary regimes for cancer patients. Med Oncol. 2017;34:108.

118. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.

119. Champ CE, Volek JS, Siglin J, Jin L, Simone NL. Weight Gain, metabolic syndrome, and breast cancer recurrence: are dietary recommendations supported by the data? Int J Breast Cancer. 2012;2012:506868.

120. Gonder U. Article on ketogenic dietary regimes for cancer highly misleading. Med Oncol. 2017;34:109.

121. Cartwright N, Howick J. Evidence-based policy: where is our theory of evidence? J Child Serv. 2009;4:6–15.

122. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, et al. Ketones and lactate “fuel” tumor growth and metastasis: evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010;9:3506–14.

123. Rodrigues LM, Uribe-Lewis S, Madhu B, Honess DJ, Stubbs M, Griffiths JR. The action of β-hydroxybutyrate on the growth, metabolism and global histone H3 acetylation of spontaneous mouse mammary tumours: evidence of a β- hydroxybutyrate paradox. Cancer Metab. 2017;5:4.

124. Cahill GFJ, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc. 2003;114:149–61.

125. Ćirković MM. Who are the SETI sceptics? Acta Astronaut. 2013;89:38–45.